References

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

10.1182/blood-2016-03-643544 · 2016 · External reference

Unraveling myelodysplastic syndromes: current knowledge and future directions

10.1007/s11912-015-0489-2 · 2016 · External reference

Myelodysplastic syndromes: clinical practice guidelines in oncology

10.6004/jnccn.2013.0104 · 2013 · External reference

Cause of death in patients with lower-risk myelodysplastic syndrome

10.1002/cncr.24984 · 2010 · External reference

International scoring system for evaluating prognosis in myelodysplastic syndromes

10.1182/blood.v89.6.2079 · 1997 · External reference

Revised international prognostic scoring system for myelodysplastic syndromes

10.1182/blood-2012-03-420489 · 2012 · External reference

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

10.1002/cncr.21792 · 2006 · External reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B

10.1200/jco.2002.04.117 · 2002 · External reference

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

10.1200/jco.2005.05.4346 · 2006 · External reference

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

10.1182/asheducation-2013.1.511 · 2013 · External reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

10.1182/blood-2009-03-209262 · 2009 · External reference

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry

10.1182/blood-2008-07-172007 · 2009 · External reference

How I treat the older patient with acute myeloid leukemia

10.1182/blood-2014-08-551499 · 2015 · External reference

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

10.3324/haematol.2011.048231 · 2012 · External reference

The role of targeted therapy in the management of patients with AML

10.1182/bloodadvances.2017009829 · 2017 · External reference

Epigenetic synergy between decitabine and platinum derivatives

10.1186/s13148-015-0131-z · 2015 · External reference

Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia

10.1038/sj.leu.2401278 · 1999 · External reference

A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia

10.1200/jco.1991.9.1.39 · 1991 · External reference

Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses

10.1200/jco.1989.7.2.173 · 1989 · External reference

Phase II clinical trial of carboplatin in relapsed and refractory leukemia

1992 · External reference

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

10.1002/cncr.11314 · 2003 · External reference

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

10.1002/cncr.25686 · 2011 · External reference

Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines

10.3109/10428190903486212 · 2010 · External reference

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study

10.1002/ajh.22092 · 2011 · External reference

Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer

10.1158/0008-5472.can-14-2391 · 2016 · External reference

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

10.1200/jco.22.02768 · 2023 · External reference

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

10.4161/epi.4.3.8694 · 2009 · External reference

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

10.1186/s13148-019-0704-3 · 2019 · External reference

Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia

10.1200/jco.2003.04.036 · 2003 · External reference

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

10.1182/blood-2005-10-4149 · 2006 · External reference

Adaptive designs in clinical trials in critically ill patients: principles, advantages and pitfalls

10.1007/s00134-018-5426-z · 2019 · External reference

Patient-reported outcomes and the evolution of adverse event reporting in oncology

10.1200/jco.2007.12.4784 · 2007 · External reference

Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells

10.1038/s41598-019-45982-7 · 2019 · External reference

Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond

10.1016/j.taap.2020.115212 · 2020 · External reference

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

10.1200/jco.2009.23.9178 · 2010 · External reference

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

10.1200/jco.2011.38.9429 · 2012 · External reference

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

10.1002/cncr.29085 · 2015 · External reference

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905

10.1200/jco.2013.50.3102 · 2014 · External reference

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup study C9710

10.1182/blood-2010-02-269621 · 2010 · External reference

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

10.1200/jco.2005.03.7903 · 2006 · External reference

Repositioning FDA-approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome

10.1158/1535-7163.mct-16-0588 · 2017 · External reference

The neutrophil

10.1016/j.immuni.2021.06.006 · 2021 · External reference

Plasticity of monocyte development and monocyte fates

10.1016/j.imlet.2020.07.007 · 2020 · External reference

Current and emerging strategies for management of myelodysplastic syndromes

10.1016/j.blre.2020.100791 · 2021 · External reference

Advances in acute myeloid leukemia: recently approved therapies and drugs in development

10.3390/cancers12113225 · 2020 · External reference

Arsenic trioxide and venetoclax synergize against AML progenitors by ROS induction and inhibition of Nrf2 activation

10.3390/ijms23126568 · 2022 · External reference

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

10.1182/blood-2018-08-868752 · 2019 · External reference

Clinical trial design in the era of precision medicine

10.1186/s13073-022-01102-1 · 2022 · External reference

Adaptive clinical trials: advantages and disadvantages of various adaptive design elements

10.1093/jnci/djx013 · 2017 · External reference